Investors Buy Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw some unusual options trading activity on Thursday. Investors bought 2,884 call options on the stock. This represents an increase of 245% compared to the typical daily volume of 835 call options.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVPH. XTX Topco Ltd purchased a new stake in Reviva Pharmaceuticals during the second quarter worth approximately $31,000. BluePointe Capital Management LLC raised its position in Reviva Pharmaceuticals by 354.7% in the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock valued at $45,000 after purchasing an additional 36,807 shares during the period. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the first quarter worth about $58,000. Ameriprise Financial Inc. purchased a new stake in shares of Reviva Pharmaceuticals in the fourth quarter worth about $84,000. Finally, Geode Capital Management LLC grew its stake in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Up 35.1%

Shares of NASDAQ:RVPH opened at $0.49 on Friday. The company has a market cap of $33.82 million, a price-to-earnings ratio of -0.75 and a beta of -0.08. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28. The firm’s 50-day simple moving average is $0.44 and its 200-day simple moving average is $0.63.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. On average, research analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Benchmark lowered their target price on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. Maxim Group decreased their price objective on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Roth Capital reiterated a “buy” rating and set a $3.00 target price (down previously from $7.00) on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th. Citigroup reissued a “buy” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 15th. Finally, Chardan Capital assumed coverage on Reviva Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $2.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Reviva Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $4.86.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.